1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €10.40 (+194.62%). The median is €10.40 (+194.62%).
| Buy |
0 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
Zivo Bioscience switches trading to OTCID platform
Zivo Bioscience has transferred its common shares to the OTCID marketplace and has been traded there since Monday. The company, with a market capitalization of $15.21 million, recorded revenue growth of 165% over the past twelve months but remains unprofitable. The stock has fallen 78% year over year and is currently trading at $3.80; existing shareholders keep their holdings. Zivo will continue to provide corporate and financial information via the OTC Markets disclosure page to ensure transparency and market presence. » More on de.investing.com
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | 100.00% |
| Gross profit | 0 | 100.00% |
| Net profit | -449.04k | 67.73% |
| EBITDA | -445.98k | 67.81% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €13.81m |
Number of shares | 3.89m |
52-week high/low | €15.16 - €0.96 |
| Dividends | No |
Beta | 0.11 |
P/E ratio | -2.93 |
PEG ratio | -0.05 |
P/B ratio | -5.03 |
P/S ratio | 242.94 |
Company profile
| Name | Zivo Bioscience |
| CEO | John Bernard Payne |
| Employees | 7 |
